Tau and A are interacting triggers and drivers within a broader and more complex pathophysiological cascade of events, demanding multi-modal biomarker-guided targeted and mechanism driven, disease-modifying therapies
Klebanoff believes the cost of the drugs will ultimately decrease as the market becomes more competitive
Appetite begins returning
A reliable AI workflow needs to preserve context: brand versus molecule : Ozempic and Wegovy are both semaglutide, but not the same market object single versus dual agonist : tirzepatide is not simply another semaglutide brand indication : diabetes, obesity, and cardiovascular risk reduction are different analytic frames funding status : PBS and private-pay populations can behave very differently time period : a 2023 shortage-period record is not equivalent to a 2026 post-shortage record source type : TGA, PBS, PBAC, company releases, media reporting, and clinical trials have different evidentiary roles The main AI risk is not that a model cannot summarise GLP-1 information
NovoCare self-pay ($199 intro, $349 ongoing) is the FDA-approved brand path
